Research Site Index

The most comprehensive
verified site database in the US

250,000+ investigator records. 186 countries. 44,000+ distinct US institution labels. Monthly refresh with real-time updates on request. The intelligence layer behind AcceleTrial.

What the RSI Is

Not a list. A sponsor-facing intelligence platform.

Most site lists in clinical research are static and unverified. RSI combines investigator search, list normalization, targeted output generation, feasibility packaging, and external market context in one sponsor-facing platform.

Monthly refresh with real-time updates on request, backed by validation-based source persistence and quality controls
Protocol-aware scoring across population fit, experience, operations, diversity, and geography, recalculated for each protocol
12 supported UI languages for global sponsor and operations teams using the RSI runtime
RSI Overview
250K+
Investigator Records
186
Countries
44K+
US Institutions
109
Specialties
12
UI Languages
2008
Founded

RSI Data Preview

What a site record looks like

Research Site Index: Query Results
Showing 5 of 1,847 matching sites, Oncology / Phase III / Eastern US
Site / Principal InvestigatorIndicationLast TrialScoreStatus
Mayo Clinic, Rochester, MN
PI: Dr. Hassan Alkhateeb, MD
Oncology
2025 Q4
9.6
Active
MD Anderson Cancer Center, Houston, TX
PI: Dr. Kenza Abbas, MD
Oncology
2026 Q1
9.4
Active
Memorial Sloan Kettering, New York, NY
PI: Dr. Wassim Abida, MD
Oncology
2025 Q3
9.1
Active
Dana-Farber Cancer Institute, Boston, MA
PI: Dr. Gregory Abel, MD
Oncology
2025 Q2
8.9
Active
Johns Hopkins Sidney Kimmel, Baltimore, MD
PI: Dr. Ahmad Al-Homsi, MD
Oncology
2024 Q4
8.6
Watch

Protocol-Aware Scoring Model

Seven dimensions. One composite score.

Every site in the RSI is scored across seven independent dimensions, recalculated for each protocol. The composite RSI score is what powers site ranking in AcceleTrial.

01
Objective Site Expertise

Therapeutic area depth, sub-specialty alignment, and prior protocol fit relative to the current study design.

02
Investigator Experience

Years on record, total trials conducted, phase distribution, and sponsor-relationship history for the named PI and sub-investigator team.

03
Access to Patients

Demographic catchment data, local disease prevalence estimates, and historical enrollment conversion for the site's relevant indication.

04
Performance Data

On-time enrollment rate, screen failure rate, protocol deviation frequency, and FDA inspection outcomes across prior trials.

05
Therapeutic Specialization

Depth of indication focus: sites with concentrated expertise in a single area score higher than broad general sites for protocol-specific studies.

06
Enrollment Reliability

Predictive enrollment velocity modeled from historical first-patient-in dates, contract-to-SIV timelines, and IRB turnaround benchmarks.

07
Protocol Compatibility

Staffing capacity, equipment on record, and prior experience with analogous study designs, structured and unstructured protocol match signals.

RSI Score Breakdown: Mayo Clinic, Rochester MN / Oncology Phase III
9.6
Composite RSI Score
Population Fit
9.5
Experience Score
8.8
Operational Score
8.5
Diversity Score
9.4
Geographic Score
7.9
Protocol Compatibility
9.7

What Each Site Record Contains

Every data point that matters for site selection

Investigator Profiles

Full PI and sub-investigator credentials, board certifications, publication history, active trial load, and years of experience by indication.

Enrollment Performance

Historical enrollment rates against projected targets, broken down by phase, indication, and sponsor type across all prior trials.

Regulatory History

FDA inspection records, audit outcomes, protocol deviation history, and Form 483 findings. Every compliance event on record.

Sponsor Relationship Data

Every prior engagement this site has had with sponsors and CROs: contracts executed, performance ratings, and communication history.

Patient Population Data

Demographic catchment analysis, disease prevalence in the site's geography, and patient pool estimates for specific indications.

Startup Velocity Metrics

IRB turnaround times, contract-to-SIV timelines, and first-patient-in dates from prior trials, giving a predictive view of activation speed.

Therapeutic Coverage

Virtually all therapeutic areas, 186 countries

The current RSI runtime exposes 109 normalized specialty options covering virtually all therapeutic areas, with 44,000+ distinct US institution labels and global coverage across 186 countries.

OncologyCardiologyNeurologyImmunologyInfectious DiseaseEndocrinologyRheumatologyPsychiatryPulmonologyGastroenterologyRare DiseaseDermatologyOphthalmologyHematologyNephrologyPain ManagementPediatricsWomen's Health

How the RSI Stays Current

Monthly refresh, real-time on request

Site data decays fast. RSI data is refreshed monthly and can be updated in real-time when requested. Validation-backed source persistence and quality controls keep the intelligence layer current.

Monthly Data Refresh

RSI data is refreshed on a monthly basis and can be updated in real time when requested by the sponsor or operations team.

Validation-Backed Quality Controls

Source persistence, shadow validation, and entity-quality workflows maintain trust in the data layer and make the intelligence asset harder to replicate.

Sponsor History Updates

Every new sponsor engagement is added to the site record as it concludes, building a longitudinal performance history over time.

Access the RSI

The verified data your
site decisions deserve

RSI access is available as a standalone product or as the data foundation behind an AcceleTrial engagement. Contact us to discuss what fits your program.

Request RSI AccessSee AcceleTrial